Molecular Residual Disease (MRD)
What MRD is?
Rapid generation of the patient-specific signature
Actionable insights from a single blood sample (< 8 mL)
Ultra-sensitive and accurate
14 working days
Real time cancer monitoring with a single blood test
After effective medical treatment, such as tumor resection, a small quantity of residual cancer cells may remain in the body, undetectable to the resolution of standard-of-care imaging scans. MRD testing enables the identification of ultra-low levels of cancer cells present in the body.
Uncovering trends by using real-world data
Circulating Tumor DNA Allows for Early Detection of Recurrence And Precise Measurement of Tumor Burden.
Our ultra-sensitive test detects molecular traces of ctDNA through comprehensive tracking of the entire tumor mutation signature including aggregating complex features such as CNV and SNV. Therefore, an ultra-low number of cells can be detected compared to standard-of-care imaging.
A standardized workflow
Our standardized workflow from the test shipment to providing MRD report has been designed to ensure consistency, accuracy, and efficiency at every stage of the process.
Filter out noise and derive patient specific cancer mutational signature
Whole genome sequencing
We identify the genetic pattern of a patient’s tumor using thousands of data points across the entire genome.
MRD technology utilizes artificial intelligence that recognizes patient-specific cancer patterns
AI & Advanced Signal Processing
MRD technology utilizes artificial intelligence that recognizes tumor specific genomic patterns to provide unprecedented acuity in cancer detection and monitoring.
Our team of oncology experts reviews each report
Clinical validation by scientific team
Our team of oncology experts reviews each report before making it available for the clinician
A technology that enables a faster time to market for pharma companies
Increase clinical trials efficiency
Enhanced efficiency, reduced overall costs, and achieve a clearer demonstration of the long-term durability of treatment responses.
Accelerate drug development
Enable Pharma partners towards genomics-driven drug development, leading to quicker and more cost-effective drug development.
Posters & publications
- AstraZeneca extends C2i pact to validate minimal residual disease solid tumor blood test
- Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer
- Sensitive detection of circulating tumor DNA by whole genome sequencing (AACR )
- Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers (AACR)
- Ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC) (AACR)
Frequently Asked Questions
C2inform is a personalized qualitative diagnostic tumor informed test for the circulating tumor DNA (ctDNA) – based Molecular Residual Disease (MRD) assessment by using whole-genome sequencing (WGS) data for patients previously diagnosed with solid cancer.
MRD test is designed to be highly sensitive and specific. It can detect extremely low levels of circulating tumor DNA (ctDNA) in a patient’s blood, allowing for the identification of residual cancer cells that might go undetected by conventional biomarker tests.
MRD test provides results in the form of a binary score (positive or negative).
Test Positive: Estimated detection score is above or equal to a pre-defined threshold value – indicates MRD detection
Test Negative: Estimated detection score is below a pre-defined threshold value – indicates MRD non-detection. A negative test result does not definitely indicate the absence of cancer.
Data is generated from WGS analysis of the following specimen types from each patient: Tumor tissue sample (Formalin Fixed Paraffin Embedded (FFPE)), whole blood for both germline DNA from Peripheral Blood Mononuclear Cells (PBMCs), and plasma for circulating tumor DNA (ctDNA).
The turnaround time is 14 Days.